OnCo

Vaginal cancer: lines of therapy

Cancer page →

4 standard-of-care settings across 3 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comers
Early / localised2
Advanced, first line1
Other settings1

Early / localised

SubgroupSettingApproachProducts and trialsEvidence
All comersStage I, small upper-vaginal lesionWide excision or brachytherapy alone in selected cases.40
All comersStage I to IVA, most patientsExternal beam radiotherapy with concurrent weekly cisplatin followed by image-guided brachytherapy, extrapolated from cervical cancer.91

Advanced, first line

SubgroupSettingApproachProducts and trialsEvidence
All comersRecurrent or metastaticPlatinum-based chemotherapy; pembrolizumab for PD-L1-positive disease by extension from cervical cancer; salvage exenterative surgery for isolated central recurrence after radiotherapy.98

Other settings

SubgroupSettingApproachProducts and trialsEvidence
All comersVAIN 2 to 3Laser ablation, topical imiquimod or fluorouracil, or excision; surveillance after treatment of CIN 3 or hysterectomy for CIN.68

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.